Print Page  |  Close Window

Investor Relations

Overview
Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, and has achieved positive pivotal trial results in patients with acute otitis externa. OTO-104 is a steroid in development for the treatment of Ménière's disease and other severe balance and hearing disorders. Two Phase 3 trials in Ménière's disease patients are underway with results expected during the second half of 2017, and a Phase 2 trial has been initiated in patients at risk for cisplatin-induced hearing loss. OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial with a Phase 2 trial expected to be initiated in the second half of 2017. Otonomy’s proprietary formulation technology utilizes a thermosensitive gel and drug microparticles to enable single dose treatment by a physician.
Stock Quote
OTIC (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$12.35
Change (%) Stock is Down 0.2 (1.59%)
Volume110,035
Data as of 04/21/17 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Stock Chart
Stock chart for: OTIC.OQ.  Currently trading at $12.35 with a 52 week high of $19.38 and a 52 week low of $10.50.
Recent NewsMore >>
DateTitle 
03/02/17Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate UpdatePrinter Friendly Version
02/28/17Otonomy to Present at Cowen and Company Health Care ConferencePrinter Friendly Version
Investor Presentations
Download Documentation Corporate Presentation – March 2, 2017
Download Documentation Investor and Analyst Day Presentation – October 7, 2016
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Otonomy Inc posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources